Image-Guided Robotic Radiosurgery for the Treatment of Same Site Spinal Metastasis Recurrences.
CyberKnife
SBRT
radiosurgery
recurrence
reirradiation (ReRT)
spinal metastasis
spine
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
15
12
2020
accepted:
18
03
2021
entrez:
14
6
2021
pubmed:
15
6
2021
medline:
15
6
2021
Statut:
epublish
Résumé
Due to recent medical advancements, patients suffering from metastatic spinal disease have a prolonged life expectancy than several decades ago, and some will eventually experience relapses. Data for the retreatment of spinal metastasis recurrences occurring at the very same macroscopic spot as the initially treated lesion are limited. Previous studies mainly included recurrences in the boundary areas as well as other macroscopic parts of the initially affected vertebrae. This study exclusively analyzes the efficacy and safety of spinal reirradiation for recurrences on the same site utilizing single-session robotic radiosurgery. Patients between 2005 and 2020 who received radiotherapy for a spinal metastasis suffering from a local recurrence were eligible for analysis. Only patients undergoing a single-session reirradiation were included. All recurrences must have been occurred in the same location as the initial lesion. This was defined as a macroscopic recurrence on computed tomography occurring at the same site as the initial spinal metastasis. All other lesions, including those in the boundary areas or other parts of the initially affected vertebrae, were excluded. Fifty-three patients with fifty-three lesions were retreated for spinal metastases. The median dose and number of fractions for the initial radiotherapy were 36 Gy and 15, respectively. Eleven patients were initially treated with stereotactic body radiotherapy. Retreatment was performed with a median dose of 18 Gy prescribed to a median isodose of 70%. The local control was 77% after a median follow-up of 22.2 months. Patients experiencing a second recurrence received a lower dose (p = 0.04), mostly below 18 Gy, and had a worse coverage (p = 0.01) than those showing local tumor control. 51% of patients experienced an improvement in pain control after treatment delivery. Besides, four vertebral compression fractures (7% of patients) but no other adverse events higher than grade 2 were observed. Single-session robotic radiosurgery appears to be a safe, time-saving, and effective treatment modality for spinal metastasis recurrences occurring in the same initial location if a considerable dose and coverage can be applied. Treatment results are comparable to reirradiated metastases in the boundary areas.
Sections du résumé
BACKGROUND
BACKGROUND
Due to recent medical advancements, patients suffering from metastatic spinal disease have a prolonged life expectancy than several decades ago, and some will eventually experience relapses. Data for the retreatment of spinal metastasis recurrences occurring at the very same macroscopic spot as the initially treated lesion are limited. Previous studies mainly included recurrences in the boundary areas as well as other macroscopic parts of the initially affected vertebrae. This study exclusively analyzes the efficacy and safety of spinal reirradiation for recurrences on the same site utilizing single-session robotic radiosurgery.
MATERIALS AND METHODS
METHODS
Patients between 2005 and 2020 who received radiotherapy for a spinal metastasis suffering from a local recurrence were eligible for analysis. Only patients undergoing a single-session reirradiation were included. All recurrences must have been occurred in the same location as the initial lesion. This was defined as a macroscopic recurrence on computed tomography occurring at the same site as the initial spinal metastasis. All other lesions, including those in the boundary areas or other parts of the initially affected vertebrae, were excluded.
RESULTS
RESULTS
Fifty-three patients with fifty-three lesions were retreated for spinal metastases. The median dose and number of fractions for the initial radiotherapy were 36 Gy and 15, respectively. Eleven patients were initially treated with stereotactic body radiotherapy. Retreatment was performed with a median dose of 18 Gy prescribed to a median isodose of 70%. The local control was 77% after a median follow-up of 22.2 months. Patients experiencing a second recurrence received a lower dose (p = 0.04), mostly below 18 Gy, and had a worse coverage (p = 0.01) than those showing local tumor control. 51% of patients experienced an improvement in pain control after treatment delivery. Besides, four vertebral compression fractures (7% of patients) but no other adverse events higher than grade 2 were observed.
CONCLUSION
CONCLUSIONS
Single-session robotic radiosurgery appears to be a safe, time-saving, and effective treatment modality for spinal metastasis recurrences occurring in the same initial location if a considerable dose and coverage can be applied. Treatment results are comparable to reirradiated metastases in the boundary areas.
Identifiants
pubmed: 34123794
doi: 10.3389/fonc.2021.642314
pmc: PMC8193921
doi:
Types de publication
Journal Article
Langues
eng
Pagination
642314Informations de copyright
Copyright © 2021 Ehret, Mose, Kufeld, Fürweger, Windisch, Haidenberger, Schichor, Tonn and Muacevic.
Déclaration de conflit d'intérêts
FE reports a grant from Ludwig-Maximilians-University Munich and honoraria from Accuray outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Neurosurg Spine. 2012 Jul;17(1):11-8
pubmed: 22578235
Lancet Oncol. 2014 Feb;15(2):164-71
pubmed: 24369114
Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):e803-9
pubmed: 22330988
Lancet Oncol. 2017 Dec;18(12):e720-e730
pubmed: 29208438
Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):819-26
pubmed: 20888133
Neuro Oncol. 2018 Aug 2;20(9):1215-1224
pubmed: 29590465
Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):937-45
pubmed: 20395063
J Korean Neurosurg Soc. 2009 Dec;46(6):538-44
pubmed: 20062569
Cancer Med. 2019 Oct;8(14):6176-6184
pubmed: 31489788
J Neurosurg Spine. 2006 Oct;5(4):303-12
pubmed: 17048766
Clin Epidemiol. 2012;4:87-93
pubmed: 22570568
Spine (Phila Pa 1976). 1990 Jan;15(1):1-4
pubmed: 2326692
Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):353-60
pubmed: 26383680
J Neurosurg Spine. 2017 Oct;27(4):428-435
pubmed: 28708043
J Neurosurg Spine. 2016 Nov;25(5):646-653
pubmed: 27341054
Pract Radiat Oncol. 2017 Nov - Dec;7(6):e409-e417
pubmed: 28673511
Lancet. 2005 Aug 20-26;366(9486):643-8
pubmed: 16112300
Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):499-506
pubmed: 20133079
Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):8-14
pubmed: 22300568
J Neurosurg Spine. 2016 Jun;24(6):928-36
pubmed: 26895526
Clin Oncol (R Coll Radiol). 2018 Feb;30(2):85-92
pubmed: 29203091
Cancer. 2011 Aug 1;117(15):3509-16
pubmed: 21319143
Spine (Phila Pa 1976). 2007 Jan 15;32(2):193-9
pubmed: 17224814
Clin Epidemiol. 2015 Jul 17;7:335-45
pubmed: 26229504
Neurosurg Focus. 2017 Jan;42(1):E6
pubmed: 28041329
Med Phys. 2010 Aug;37(8):4078-101
pubmed: 20879569
J Neurosurg Spine. 2007 Aug;7(2):151-60
pubmed: 17688054
Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1207-1215
pubmed: 29029886